<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Preconditioning the brain with volatile <z:chebi fb="37" ids="38867">anesthetics</z:chebi> seems to be a viable option for reducing ischemic cerebral injury </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is uncertain whether this preconditioning effect extends over a longer period of time </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to determine if <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> preconditioning offers durable neuroprotection against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Rats (Sprague-Dawley) were randomly allocated to two groups: nonpreconditioned control group (n = 44) and preconditioned group (n = 45) exposed to 2.7 vol% <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> (45 min) 60 min before surgery </plain></SENT>
<SENT sid="4" pm="."><plain>Animals in both groups were anesthetized with 3.0 vol% <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> and subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>After 60 min of awake focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, the filament was removed </plain></SENT>
<SENT sid="6" pm="."><plain>Functional neurologic outcome (range 0-18; 0 = no deficit), cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size (Nissl staining), and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (Terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="16450">2'-deoxyuridine</z:chebi> 5'-<z:chebi fb="0" ids="15266,18036">triphosphate</z:chebi> nick-end labeling; cleaved caspase-3 staining) were evaluated at 3, 7, and 14 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:chebi fb="0" ids="9130">Sevoflurane</z:chebi> preconditioning significantly improved functional outcome and reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (109 +/- 43 vs. 148 +/- 56 mm(3)) 3 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> compared to the control group </plain></SENT>
<SENT sid="8" pm="."><plain>However, after 7- and 14-day recovery periods, no significant differences were observed between groups </plain></SENT>
<SENT sid="9" pm="."><plain>The number of apoptotic cells was significantly lower in the preconditioned group than in the control group after 3- and 7-day recovery periods </plain></SENT>
<SENT sid="10" pm="."><plain>Fourteen days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, no differences were observed between groups </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: In this model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> preconditioning induced effective but transient neuroprotective effects </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="9130">Sevoflurane</z:chebi> preconditioning also decreased <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a more sustained way because it was observed up to 7 days after injury </plain></SENT>
</text></document>